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attenuated calcification progression appears highly
speculative.
(3) Very consistently, all epidemiological studies have noted
that the extent of cardiovascular calcifications in HD
patients is a potent predictor of cardiovascular outcomes
including death. We now have two prospective trials,
the 4D study [1] and the AURORA study [2], in which
despite excellent LDL cholesterol control with a statin,
cardiovascular outcomewas not affected inHDpatients.
If LDL cholesterol were indeed a major determinant of
calcification progress, one would have expected to see
a benefit, in particular, in high-risk patients such as the
diabetic dialysis patients of 4D.
The fact is that we currently have no evidence for a
major role of LDL cholesterol in driving cardiovascular
calcifications and mortality in HD patients.
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Azathioprine, the Cinderella in the treatment of lupus
nephritis
Sir,
With interest I read the contribution of Dr Joanne Bargman
on the use of cyclophosphamide in the treatment of lu-
pus nephritis [1]. Although not fully supported by the data,
the i.v. pulses of cyclophosphamide became the gold stan-
dard for treatment of proliferative lupus nephritis. In sev-
eral analyses [2,3], azathioprine gave at least comparable
results as cyclophosphamide, but with a much better toxic-
ity profile. Nevertheless, azathioprine became the forgotten
Cinderella in this therapeutic scenery and was regarded as
second-class treatment. The author then describes that, al-
though it seemed appropriate, the use of azathioprine was
not discussed at all in two major nephrology conferences
she attended. So it was surprising to note that Dr Bargman
did not discuss the only head to head comparison between
i.v. cyclophosphamide and azathioprine [4,5]. This random-
ized controlled trial, comparing i.v. cyclophosphamide with
three times three pulses of methylprednisolone and 2mg/kg
azathioprine, in the Netherlands in 87 patients with biopsy-
proven proliferative lupus nephritis showed after a median
follow-up of 77 months that
• the occurrence of partial or complete remissions was
equal in both arms;
• non-sustained doubling of serum creatinine occurred
more frequently in the AZA group (RR 5.2; 95% CI
1.1–25.2; P = 0.04) [5];
• renal flares occurred more frequently in the AZA group
(RR 4.9; 95%, CI 1.6–15.0; P 0.006);
• renal flares responded to intensivation of treatment in all
patients;
• at the last follow-up, there were no differences between
the groups in median serum creatinine (82 µmol/l; IQR:
74–108) and median proteinuria (0.3 g/24 h; IQR: 0.10–
0.72);
• in repeat biopsies after 2 years in both groups, the
activity index decreased similarly, but the chronicity
index decreased slightly in the CY group (2.8–3.0), but
in the AZA group, this increase was larger (2.8–3.8;
P = 0.05);
• at the last follow-up, 88% of the patients in the AZA
group had been free of cyclophosphamide treatment and
had therefore a better prognosis regarding fertility.
These results show that azathioprine is not the first drug
of choice for induction treatment in patients with lupus
nephritis. However, if a patient chooses not to jeopardize
fertility, azathioprine forms an alternative. Also, during
pregnancy, azathioprine is relatively safe in contrast to my-
cophenolate mofetil (MMF) or cyclophosphamide, which
are contraindicated. Therefore, azathioprine still has a (lim-
ited) place in the induction treatment of lupus nephritis.
As maintenance treatment, azathioprine is probably a good
choice. In the Euro-Lupus Trial, azathioprine started af-
ter 3 months gave comparable results as i.v. cyclophos-
phamide given for 1 year [6,7]. The upcoming results of the
MAINTAIN-trial will give better insight into the compar-
ison of azathioprine with MMF as maintenance treatment
[8]. In a recent meta-analysis, the results of azathioprine
and MMF during maintenance were comparable, although
the number of patients in this analysis was rather low [9].
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Reply
Sir,
I would like to thank Dr Berden for his response to my
editorial ‘How did cyclophosphamide become the drug
of choice for lupus nephritis?’ [1]. As I emphasized in
the paper, the editorial did not purport to provide an in-
depth review of every study of immunosuppression in lu-
pus nephritis. In particular, I chose not to discuss the study
by Grootscholten et al. [2] because of the unbalanced treat-
ment protocol that compared pulsed intravenous cyclophos-
phamide combined with daily oral prednisone with azathio-
prine in combination with pulse methylprednisolone. In ad-
dition, because the results were reported as relative risks, it
was difficult to interpret the outcomes in this cohort of 87
patients.
AlthoughDrBerden says in this letter that ‘non-sustained
doubling of serum creatinine occurred more frequently in
the AZA groups (RR 5.2; 95% CI 1.1–25.2; P = 0.04)’,
in the actual publication it reports: ‘The proportion of pa-
tients that reached the primary end point (non-sustained
doubling of initial serum creatinine) did not differ signifi-
cantly between the two arms’ [2]. To clarify, it is only in the
follow-up renal biopsy study [3] of less than half of the orig-
inal cohort, published in a rheumatology journal [4], that
nine patients reached the end-point of sustained or non-
sustained doubling of serum creatinine, and this outcome
was more frequent in the azathioprine-treated group. The
median chronicity index did increase more in this group,
but, as the authors noted, none of the examined pathological
variables predicted long-term renal function [3].
Unfortunately, the data in the two studies by
Grootscholten et al. are not sufficient to supportDrBerden’s
conclusion that ‘azathioprine is not the first drug of choice
for induction treatment in patients with lupus nephritis’.
Rather than trying to make a generalized statement about
therapy to fit all patients, my editorial is a plea to remem-
ber that there exists a choice in treatment, with insufficient
evidence to promote one therapy or another as the ‘gold
standard’.
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